New Study Results Published – Lilly GZGI

Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,

GSK Announces Positive Data for its Respiratory Syncytial Virus Vaccine Candidate for Older Adults 

JoinAStudy.ca Investigators Dr. Peter Dzongowski, Dr. Michael Jones and Dr. Sean Peterson were all recently involved in GSK trial AReSVi 006, evaluating a vaccine candidate for Respiratory Syncytial Virus (RSV). Recruitment was highly successful for all three investigators, whose work has helped lead to the first RSV vaccine candidate to show statistically significant and clinically